What is LUMAKRAS®?

LUMAKRAS® is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body or cannot be removed by surgery, and whose tumor has an abnormal KRAS G12C gene, and who have received at least one prior treatment for their cancer.

Your healthcare provider will perform a test to make sure that LUMAKRAS® is right for you. It is not known if LUMAKRAS® is safe and effective in children.

For US Audiences Only Approved Use Patient Information Full Prescribing Information Important Safety Information Select Cancer Type For Health Care Professionals

You are about to leave the lumakras.com/nsclc website and enter a website operated by a third party. Amgen is not responsible for and does not endorse or control the content contained on this third-party website.

Continue
Laurie S., a smiling current LUMAKRAS® patient

How can I learn more?

Be your own biggest advocate. Every time I meet with my doctor, I bring a list of questions.”

Patient story represents individual’s experience with LUMAKRAS®. Results may vary.

– Laurie S.
current LUMAKRAS® patient

how do i take lumakras

How can I prepare to talk to my doctor about non-small cell lung cancer (NSCLC) and KRAS G12C?

Sometimes it’s challenging to discuss all of your questions and concerns in one doctor visit. Here are some considerations to help organize your thoughts*

Before your appointment:
  • Write down things you want to discuss. Put the most important topics at the top so you get to them first
  • Think about bringing a friend or loved one with you, or have them present if you are doing a video call
  • Here are some topics that may be helpful to ask your doctor about:
    • What is my biomarker status?
    • Why am I being put on treatment?
    • How does the treatment work?
    • What should I expect from treatment?
During your appointment:
  • You may want to ask about your biomarker status
    • If you don’t know whether or not you’ve had a biomarker test, talk to your doctor
    • If you have had a biomarker test, ask your doctor for the results
    • You may want to keep those results somewhere safe for future appointments. They could be helpful at visits when you talk about treatment
After your appointment:
  • If you change doctors, consider sharing the results of your biomarker test with your new doctor
  • Think about organizing information on biomarker testing and treatment in an easy-to-access location

*Amgen cannot make any clinical recommendations or render medical or nursing advice, treatment, opinions, or care. The above is not intended to be a source of medical advice or treatment and does not, in any way, replace independent medical advice regarding your diagnosis or treatment.

How can I learn more about LUMAKRAS®?

Talk to your doctor about the right treatment for you and any questions you may have. As you navigate your treatment journey for NSCLC, here are some resources you may find helpful.

Dosing GuideDosing Guide

LUMAKRAS® Patient Brochure
Dosing GuideDosing Guide

LUMAKRAS® Dosing Guide
Dosing GuideDosing Guide

Getting Started With LUMAKRAS® Patient Access Roadmap
See how Amgen may be able to help

Important Safety Information

What should I tell my healthcare provider before taking LUMAKRAS®?

  • Before taking LUMAKRAS®, tell your healthcare provider about all your medical conditions, including if you:
    • have liver problems.
    • have lung or breathing problems other than lung cancer.
    • are pregnant or plan to become pregnant. It is not known if LUMAKRAS® will harm your unborn baby.
    • are breastfeeding or plan to breastfeed. It is not known if LUMAKRAS® passes into your breast milk. Do not breastfeed during treatment with LUMAKRAS® and for 1 week after the final dose.
  • Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, dietary and herbal supplements. LUMAKRAS® can affect the way some other medicines work, and some other medicines can affect the way LUMAKRAS® works.
  • Especially tell your healthcare provider if you take antacid medicines, including Proton Pump Inhibitor (PPI) medicines or H2 blockers during treatment with LUMAKRAS®. Ask your healthcare provider if you are not sure.

LUMAKRAS® may cause serious side effects, including:

  • Liver Problems: LUMAKRAS® may cause abnormal liver blood test results. Your healthcare provider should do blood tests before starting and during treatment with LUMAKRAS® to check liver function. Tell your healthcare provider right away if you get any signs or symptoms of liver problems, including: your skin or the white part of your eyes turns yellow (jaundice), dark or “tea-colored” urine, light-colored stools (bowel movements), tiredness or weakness, nausea or vomiting, bleeding or bruising, loss of appetite, and pain, aching, or tenderness on the right side of your stomach-area (abdomen).
  • Lung or breathing problems: LUMAKRAS® may cause inflammation of the lungs that can lead to death. Tell your healthcare provider or get emergency medical help right away if you have new or worsening shortness of breath, cough, or fever.
  • Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with LUMAKRAS® if you develop side effects.

The most common side effects

  • The most common side effects of LUMAKRAS® include diarrhea, muscle or bone pain, nausea, tiredness, liver problems, cough, changes in liver function tests, and changes in certain blood tests.
  • These are not all the possible side effects of LUMAKRAS®. Call your doctor for medical advice about side effects.

What is LUMAKRAS®?

LUMAKRAS® is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body or cannot be removed by surgery, and whose tumor has an abnormal KRAS G12C gene, and who have received at least one prior treatment for their cancer. Your healthcare provider will perform a test to make sure that LUMAKRAS® is right for you. It is not known if LUMAKRAS® is safe and effective in children.

Please see LUMAKRAS® full Prescribing Information.

References: 1. NCI Dictionary of Cancer Terms. www.cancer.gov. Accessed January 27, 2025. 2. LUMAKRAS® (sotorasib) prescribing information, Amgen. 3. Ryan MB, et al. Nat Rev Clin Oncol. 2018;15:709-720. 4. Hong DS, et al. N Engl J Med. 2020;383:1207-1217. 5. Data on file, Amgen; [Analysis of AACR Genie v12].

References: 1. Hong DS, et al. N Engl J Med. 2020;383:1207-1217. 2. NCI Dictionary of Cancer Terms. www.cancer.gov. Accessed January 27, 2025. 3. LUMAKRAS® (sotorasib) prescribing information, Amgen. 4. Sotorasib CSR. Amgen; 2021. 5. Data on file, Amgen; [KRAS G12C Trials Sites]. 6. LUMAKRAS® (sotorasib) patient information, Amgen.

References: 1. LUMAKRAS® (sotorasib) patient information, Amgen. 2. LUMAKRAS® (sotorasib) prescribing information, Amgen. 3. Data on file, Amgen; [Sotorasib Tablet Size].

Important Safety Information

What should I tell my healthcare provider before taking LUMAKRAS®?

  • Before taking LUMAKRAS®, tell your healthcare provider about all your medical conditions, including if you:
    • have liver problems.
    • have lung or breathing problems other than lung cancer.